No. They need to prove that new partner, Artiva cbNK cells, works like MDACC cbNK. Artiva collaboration was announced 2 years ago and it was Sept that they had sufficient data to close the deal. FDA 2nd mtg beginning of year and IND filing after that.
The ~6000 initial market includes AFM13 mono and combo with PD-1. ~2000 r/r HL would be addressable with AFM13-cbNK.
What do you think would be more realistic if above are not IYO?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.